Orbis Allan Gray LTD Genmab A/S Transaction History
Orbis Allan Gray LTD
- $15.3 Billion
- Q2 2025
A detailed history of Orbis Allan Gray LTD transactions in Genmab A/S stock. As of the latest transaction made, Orbis Allan Gray LTD holds 7,920,400 shares of GMAB stock, worth $222 Million. This represents 1.07% of its overall portfolio holdings.
Number of Shares
7,920,400
Previous 5,710,741
38.69%
Holding current value
$222 Million
Previous $112 Million
46.34%
% of portfolio
1.07%
Previous 0.8%
Shares
4 transactions
Others Institutions Holding GMAB
# of Institutions
241Shares Held
65.1MCall Options Held
32.5KPut Options Held
55K-
Alliancebernstein L.P. New York, NY10.7MShares$298 Million0.08% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$142 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.57MShares$99.9 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.45MShares$96.7 Million0.05% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.92MShares$81.8 Million0.42% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $18.4B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...